The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Celecoxib & Cardiovascular Death: NSAID Safety Under Review

Celecoxib & Cardiovascular Death: NSAID Safety Under Review

December 7, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to adverse cardiovascular effects and serious skin reactions.3 The U.S. Food and Drug Administration (FDA) allowed celecoxib to remain on the market, but mandated a cardiovascular safety trial.4,5 The results of this trial, Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen or Naproxen (PRECISION), were recently published.6

You Might Also Like
  • Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed
  • Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk
  • Ibuprofen More Likely to Raise BP than Naproxen or Celecoxib
Also By This Author
  • Long-Term Data Show Baricitinib Is Safe & Effective for RA

PRECISION Safety Trial
This was a randomized, multicenter, double-blind, noninferiority trial in 24,081 patients with osteoarthritis or rheumatoid arthritis, and with increased cardiovascular risk. Randomization was stratified by the patients’ primary diagnosis, aspirin use and geographic location. The trial goal was to assess the non-inferiority of celecoxib with regard to the primary composite outcome of cardiovascular death.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients were treated with celecoxib (100 mg twice daily), ibuprofen (600 mg three times daily) or naproxen (375 mg twice daily) for a mean duration of 20.3±16 months, with a mean follow-up of 34.1±13.4 months. Investigators could increase the celecoxib dose to 200 mg twice daily, ibuprofen to 800 mg three times daily or naproxen to 500 mg twice daily, following the first visit. All participants were provided with esomeprazole 20–40 mg for gastric protection. Patients who were receiving low-dose aspirin (<325 mg) were allowed to continue using it.

The primary composite outcome was the first occurrence of an adverse event that met Antiplatelet Trialists Collaboration (APTC) criteria. These criteria included death due to cardiovascular causes (including hemorrhage), nonfatal myocardial infarction or nonfatal stroke. A secondary composite outcome, major adverse cardiovascular events, included components of the primary outcome plus coronary revascularization, hospitalization for unstable angina, or transient ischemic attack. Clinically significant gastrointestinal (GI) events were also secondary outcomes. Tertiary outcomes included iron deficiency anemia (GI origin), clinically significant renal events, and heart failure or hypertension hospitalization. A non-adjudicated secondary outcome was arthritis pain intensity, which was assessed using a Visual Analogue Scale (VAS) (scores range from 0 to 100 mm, higher scores equal worse pain). Noninferiority required a hazard ratio of 1.12 or lower, as well as an upper 97.5% confidence limit of 1.33 or lower in the intention-to-treat population and 1.40 or lower in the on-treatment population.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The trial duration was 10 years, and 90% of the participants had osteoarthritis, while 10% had rheumatoid arthritis. During the trial, 69% of the patients stopped taking the study drug, and 27% of patients discontinued follow-up.

Pages: 1 2 3 | Single Page

Filed Under: Analgesics, Drug Updates, Safety Tagged With: cardiovascular, FDA, Food and Drug Administration, heart, NSAIDs, PREC

You Might Also Like:
  • Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed
  • Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk
  • Ibuprofen More Likely to Raise BP than Naproxen or Celecoxib
  • A Comprehensive Review of NSAID Cardiovascular Toxicity

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.